| Antithrombotic strategies for the management of non-valvular atrial fibrillation. | |
| | |
MedLine Citation:
|
PMID: 15823624 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Atrial fibrillation (AF) is the most common cardiac arrhythmia, affecting an estimated 2.2 million Americans. The management of non-valvular AF is likely to become even more challenging over the coming decades. The treatment target of AF takes 3 forms: cardioversion, rate control, and minimization of embolic risk. Recently, rate, rather than rhythm control has emerged as a valid therapeutic option in patients with persistent AF. According to current guidelines, International Normalized Ratio-targeted oral anticoagulation and proper stratification of risk remain fundamental principles of management. This article reviews, in depth, the current therapeutic options for atrial fibrillation including oral anticoagulants and unfractionated heparin, as well as reviewing new therapeutic options including bridging therapy with low-molecular-weight heparins and the new oral antithrombotic drug, ximelagatran. |
| | |
Authors:
|
Uwe Nixdorff |
Related Documents
:
|
17011134 - Atrial fibrillation may be a vascular disease: the role of the pulmonary vein. 18044014 - Mechanism of recurrence after radiofrequency catheter ablation of atrial fibrillation g... 10532504 - Regional endocardial mapping of spontaneous and induced atrial fibrillation in patients... 14739714 - Rationale for the atrial fibrillation and congestive heart failure (af-chf) trial. 22869254 - Removing the cells from adult bone marrow derived stem cell therapy does not eliminate ... 17011134 - Atrial fibrillation may be a vascular disease: the role of the pulmonary vein. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: International journal of cardiology Volume: 100 ISSN: 0167-5273 ISO Abbreviation: Int. J. Cardiol. Publication Date: 2005 Apr |
Date Detail:
|
Created Date: 2005-04-12 Completed Date: 2005-07-25 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8200291 Medline TA: Int J Cardiol Country: Ireland |
Other Details:
|
Languages: eng Pagination: 191-8 Citation Subset: IM |
Affiliation:
|
Friedrich-Alexander-Universität, Medizinische Klinik II mit Poliklinik, Erlangen, Germany. uwe.nixdorff@rzmail.uni-erlangen.de |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Administration, Oral Anticoagulants / therapeutic use* Atrial Fibrillation / drug therapy* Azetidines / therapeutic use Benzylamines Combined Modality Therapy Echocardiography, Transesophageal Electric Countershock Fibrinolytic Agents / therapeutic use* Heparin, Low-Molecular-Weight / therapeutic use Humans |
| Chemical | |
Reg. No./Substance:
|
0/Anticoagulants; 0/Azetidines; 0/Benzylamines; 0/Fibrinolytic Agents; 0/Heparin, Low-Molecular-Weight; 0/ximelagatran |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Myocardial ischemia/reperfusion-injury, a clinical view on a complex pathophysiological process.
Next Document: MORE--MOexipril and REgression of left ventricle hypertrophy in combination therapy A multicentric o...